Fig 1.
Participant Flow diagram.
Table 1.
Summary of SSRI and antidepressant exposures and congential anomaly (CA) prevalence in 3 countries: Denmark, Norway, Wales.
Table 2.
SSRI exposure 91 days either side of LMPa by individual SSRIb and dose: 3 countries.
Table 3.
SSRI (NO6AB) exposures 91 days either side of LMPa and outcomesbbased on signals: 3 countries.
Table 4.
High Dose exposurea and ‘all anomalies’, CHD, severe CHD, ‘Stillbirth or Anomaly’: 3 countries.
Table 5.
Congenital anomalies and stillbirths and SSRI exposure LMP±91 daysa: analyses adjusted for smoking and socio-economic status (SES).
Table 6.
Comparisons of stopping before pregnancy, pausing during pregnancy, exposure LMP±91 daysa, and unexposed for 11 quartersb for all anomalies, CHD and severe CHD, including receipt of >0 and >1 prescriptions: 3 countries.
Table 7.
Depression, medicated and unmedicated and congenital anomalies and stillbirths in Wales.a
Table 8.
Subgroup explorations in Wales: SSRI exposure and congenital anomalies or Stillbirths.a